



First-quarter 2026

Worldwide sales

\$11.2B

↑3.7%¹

On a comparable basis*

Adjusted diluted EPS

\$1.15²

↑6%

Updated full-year 2026 guidance³

6.5% to 7.5%

Comparable sales growth

\$5.38 to \$5.58

Adjusted diluted EPS

Reflects \$0.20 dilution related to Exact Sciences acquisition

First-quarter sales for key business units



\$5.5B

Medical Devices



\$2.2B

Diagnostics



\$2.0B

Nutrition



\$1.4B

Established
Pharmaceuticals

First-quarter business highlights



Transforming cancer care

- Completed acquisition of Exact Sciences, positioning Abbott as a leader in fast-growing cancer screening and diagnostics.
- Abbott's new cancer diagnostics portfolio spans the continuum of care—from early detection tools like Cologuard® for colorectal cancer and the multi-cancer test Cancerguard® to treatment-guiding Oncotype DX® for breast cancer to monitoring tools like Oncodetect®, which detects molecular residual disease.



Accelerating innovation with over 200 ongoing clinical trials

- Positive results from the VERITAS study show clinically meaningful closure rates for the investigational Amulet 360™ Left Atrial Appendage Occluder, a device designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
- FreeDM2 randomized control trial results show that FreeStyle Libre 3 delivered better glucose outcomes than fingersticks in people with Type 2 diabetes on basal insulin.



Advancing cardiac rhythm management solutions

- Abbott is collaborating with AtaCor Medical to develop a next-generation extracardiac implantable cardioverter defibrillator.
- System designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.

*Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments received by the Structural Heart business under a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

1. On a GAAP basis, first-quarter Abbott sales increased 7.8%. 2. First-quarter 2026 GAAP diluted EPS was \$0.61. 3. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.